TY  - JOUR
AU  - Burwitz, B.J.*
AU  - Wettengel, J.M.
AU  - Mück-Häusl, M.
AU  - Hammond, K.B.*
AU  - Ringelhan, M.
AU  - Ko, C.
AU  - Reed, J.*
AU  - Norris, R.*
AU  - Park, B.*
AU  - Moller-Tank, S.*
AU  - Esser, K.
AU  - Greenel, J.*
AU  - Wu, H.*
AU  - Abdulhaqq, S.*
AU  - Webb, G.*
AU  - Sutton, W.F.*
AU  - Klug, A.*
AU  - Swanson, T.*
AU  - Legasse, A.W.*
AU  - Asokan, A.*
AU  - Haigwood, N.L.*
AU  - Protzer, U.
AU  - Sacha, J.B.*
C1  - 54489
C2  - 45579
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 324-324
TI  - A new HIV/HBV co-infection model: Hepatocytic expression of human sodium taurocholate cotransporting polypeptide (NTCP) Enables Hepatitis B Virus Infection of Macaques.
JO  - J. Med. Primatol.
VL  - 47
IS  - 5
PB  - Wiley
PY  - 2018
SN  - 0047-2565
ER  - 

TY  - JOUR
AB  - he long-term benefits of highly active antiretroviral therapy in HIV-infected patients are limited by emergence of drug-resistant variants and side effects. Therefore, we studied the concept of therapeutic immunization in 18 rhesus monkeys infected with a highly pathogenic simian immunodeficiency virus (SIV) swarm. METHODS: Monkeys were treated with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) for 19 weeks starting 10 days after infection. After suppression of viremia, one group of monkeys was immunized with recombinant modified vaccinia virus Ankara (MVA) vectors expressing gag-pol and env. A second group received MVA vectors expressing the regulatory genes tat, rev and nef, while a third group was not immunized. RESULTS: Immunization with gag-pol and env expressing MVA enhanced SIV antibody titers. Following discontinuation of PMPA treatment, a rebound in viral load was observed. However, in three of six monkeys immunized with MVA gag-pol and MVA env, and two of six monkeys immunized MVA expressing regulatory genes set point RNA levels were below or close to a threshold level of 10(4) RNA copies/ml, while only one of six unvaccinated monkeys maintained such low RNA levels. CONCLUSIONS: Although a subset of animals seem to benefit from therapeutic immunization with MVA vectors, the difference in set point RNA levels between the groups did not reach statistical significance.
AU  - Überla, K.*
AU  - Rosenwirth, B.
AU  - Ten Haaft, P.*
AU  - Heeney, J.*
AU  - Sutter, G.
AU  - Erfle, V.
C1  - 3598
C2  - 24712
SP  - 2-9
TI  - Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy.
JO  - J. Med. Primatol.
VL  - 36
IS  - 1
PY  - 2007
SN  - 0047-2565
ER  - 

TY  - JOUR
AU  - Rosenwirth, B.*
AU  - Bogers, W.M.J.M.*
AU  - Nieuwenhuis, I.G.*
AU  - Ten Haaft, P.*
AU  - Niphuis, H.*
AU  - Kuhn, E.M.*
AU  - Bischofberger, N.*
AU  - Erfle, V.
AU  - Sutter, G.
AU  - Berglund, P.*
C1  - 21257
C2  - 19368
SP  - 195-205
TI  - An anti-HIV strategy combining chemotherapy and therapeutic vaccination.
JO  - J. Med. Primatol.
VL  - 28
PY  - 1999
SN  - 0047-2565
ER  -